English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 26 January 2021, 11:58 JST
Share:
    

Source: Eisai
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time

TOKYO, Jan 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that it has been listed in the 2021 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's fifth inclusion on the list. Ranked 16rd, Eisai was the highest ranking company among global pharmaceutical companies. Also, Eisai became the highest ranking Japanese company among the five Japanese companies listed in the Global 100.

The Global 100 evaluates the sustainability of approximately 8,100 of the world's major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year at the World Economic Forum in Davos week. The Global 100 is based on up to 24 key performance indicators covering clean revenue, financial management, supplier performance, employee management and resource management, with the evaluations carried out based on data publicly disclosed in financial filings, integrated reports, or through other such channels. Eisai received high evaluation particularly on clean revenue and investment*, as well as employee safety and stability.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this corporate philosophy, Eisai is striving to sustainably enhance corporate value by strengthening its ESG initiatives and increasing non-financial value.

* Sales revenue, R&D cost and investment for products such as medicines which are under equitable pricing strategies and included in the WHO Essentials Medicines Lists or used to treat any of in scope diseases, conditions and pathogens defined by the ATM Index Foundation.

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Tuesday, 5 November 2024, 11:35 JST
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Friday, 1 November 2024, 13:56 JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Thursday, 31 October 2024, 13:56 JST
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Thursday, 31 October 2024, 11:33 JST
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Thursday, 17 October 2024, 20:01 JST
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575